ACRV
Acrivon Therapeutics, Inc. Common Stock NASDAQ$2.17
Mkt Cap $68.5M
52w Low $1.05
44.6% of range
52w High $3.56
50d MA $1.64
200d MA $1.80
P/E (TTM)
-1.0x
EV/EBITDA
-0.7x
P/B
0.7x
Debt/Equity
0.0x
ROE
-69.2%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
1.74
50d MA
$1.64
200d MA
$1.80
Avg Volume
833.9K
About
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific p…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.49 | -0.49 | +0.0% | 1.70 | -0.6% | -2.4% | -5.9% | -7.1% | -10.6% | -16.5% | — |
| Nov 13, 2025 | AMC | -0.57 | -0.47 | +17.5% | 2.07 | -2.9% | +8.2% | +15.0% | +17.4% | +14.0% | +9.2% | — |
| Aug 13, 2025 | AMC | -0.57 | -0.55 | +3.5% | 1.31 | +4.6% | +6.1% | +3.1% | +6.1% | -0.8% | -0.8% | — |
| May 14, 2025 | AMC | -0.57 | -0.51 | +10.5% | 1.14 | +0.0% | -3.5% | +0.9% | +3.5% | +9.6% | +0.9% | — |
| Mar 27, 2025 | AMC | -0.69 | -0.60 | +13.0% | 2.52 | -1.6% | -11.1% | -19.4% | -33.3% | -31.0% | -34.9% | — |
| Nov 13, 2024 | AMC | -0.56 | -0.59 | -5.4% | 7.93 | +0.3% | -0.1% | -12.2% | -20.9% | -19.5% | -18.0% | — |
| Aug 13, 2024 | AMC | -0.59 | -0.52 | +11.9% | 7.25 | +1.4% | -3.2% | -0.3% | +4.8% | +14.9% | +24.6% | — |
| May 14, 2024 | AMC | -0.89 | -0.73 | +18.0% | 8.36 | +2.6% | +3.5% | +2.4% | +6.3% | +2.3% | -1.8% | — |
| Mar 28, 2024 | AMC | -0.72 | -0.86 | -19.4% | 7.15 | -0.8% | +1.4% | -6.4% | -6.9% | -6.4% | -9.4% | — |
| Nov 9, 2023 | AMC | -0.72 | -0.66 | +8.3% | 4.59 | +4.4% | -4.7% | -0.7% | +10.7% | +13.1% | -3.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.93 | $1.95 | +1.0% | -9.3% | -15.5% | -11.9% | -5.2% | -3.1% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.37 | +0.4% | -1.7% | +0.0% | +0.0% | +2.5% | -6.8% |
| Aug 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.31 | $1.37 | +4.6% | +6.1% | +3.1% | +6.1% | -0.8% | -0.8% |
| May 16 | Jones Trading | Downgrade | Buy → Hold | — | $1.10 | $1.12 | +1.8% | +4.5% | +7.3% | +13.6% | +4.5% | +4.5% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.14 | $1.14 | +0.0% | -3.5% | +0.9% | +3.5% | +9.6% | +0.9% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.52 | $2.48 | -1.6% | -11.1% | -19.4% | -33.3% | -31.0% | -34.9% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.48 | -1.6% | -11.1% | -19.4% | -33.3% | -31.0% | -34.9% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $4.26 | -21.0% | -51.6% | -53.2% | -58.4% | -62.3% | -68.8% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.39 | $4.26 | -21.0% | -51.6% | -53.2% | -58.4% | -62.3% | -68.8% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.39 | $4.26 | -21.0% | -51.6% | -53.2% | -58.4% | -62.3% | -68.8% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K disclosure safeguards ACRV from liability for voluntary information sharing, but provides no material news about business performance or strategy changes affecting stock valuation.
Mar 19
8-K
Acrivon Therapeutics, Inc. -- 8-K Filing
Acrivon terminated its diagnostic partnership with Quanterix but secured continued clinical testing support during transition to Acrivon's CLIA laboratory for its ACR-368 oncology study.
Mar 2
8-K · 7.01
! Medium
Acrivon Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Acrivon Therapeutics disclosed positive interim ACR-368 clinical data for endometrial cancer treatment at a key opinion leader panel, supporting the drug's potential to address unmet serous subtype needs.
Feb 27
Data updated apr 24, 2026 10:42am
· Source: massive.com